Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115668) titled 'Study on the efficacy and safety of NALIRIFOX in combination with Iparomlimab and Tuvonralimab Injection and SBRT as neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors' on Dec. 30, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital, Sichuan Universit
Condition:
Intrahepatic cholangiocarcinoma
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-12
Target Sample Size: Experimental Group:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj....